Rate Control vs Rhythm Control in AF: How I Decide for My Patients

The central question in AF management

When a patient is first diagnosed with atrial fibrillation and has understood the basics of what the condition involves, the natural next question is: what do we do about it? The treatment landscape for AF has two fundamental approaches, and choosing between them — or combining them — is one of the most nuanced decisions in cardiology.

Rate control accepts that the heart will remain in AF, but uses medication to keep the ventricular rate within a safe range, typically below 110 beats per minute. Rhythm control actively attempts to restore and maintain normal sinus rhythm. These strategies are not mutually exclusive — but understanding the logic behind each helps patients engage meaningfully with the decision.

Rate Control: When It Makes Sense

Rate control uses medication to slow the rate at which the irregular atrial signals pass through the AV node to the ventricles. The most commonly used drugs are beta-blockers (bisoprolol, metoprolol), rate-limiting calcium channel blockers (diltiazem, verapamil), and occasionally digoxin. The goal is to ensure the heart rate is not excessively fast during AF — because it is the fast, sustained rate that causes the most harm to the heart muscle over time.

Rate control is appropriate in a number of situations: older patients with minimal symptoms, patients in whom rhythm control has been attempted without success, or those where comorbidities make ablation unsuitable. For patients with permanent AF — where a joint decision has been made not to pursue rhythm control — rate control and anticoagulation form the backbone of management.

Rhythm Control: The Case for Earlier Intervention

Rhythm control strategies aim to restore normal sinus rhythm and keep it there. The options include antiarrhythmic drugs — flecainide, propafenone, amiodarone, sotalol — electrical cardioversion, and catheter ablation. Each has its role, and they are often used in combination.

The evidence base for early rhythm control has shifted substantially in recent years. The EAST-AFNET 4 trial, published in 2020, was a landmark study. It recruited over 2,600 patients with early AF — diagnosed within the previous 12 months — and randomised them to early rhythm control versus usual care (predominantly rate control). The early rhythm control group showed a significant reduction in the composite of cardiovascular death, stroke, hospitalisation for worsening heart failure, and acute coronary syndrome. Crucially, this benefit was present even in patients with relatively mild symptoms — overturning the previous assumption that rhythm control only mattered for highly symptomatic patients.

The 2024 ESC AF guidelines have embedded this evidence. They now recommend considering early rhythm control in all patients with newly diagnosed AF, with catheter ablation given a Class 1A recommendation as first-line rhythm control therapy for symptomatic paroxysmal AF and selected patients with persistent AF.

How I Make the Decision

In practice, my decision framework for each new patient involves weighing several factors together:

• Symptom burden — a patient who is breathless, fatigued, or unable to exercise is a strong candidate for rhythm control
• Age and fitness — younger, fitter patients generally benefit more from ablation and tolerate it well
• AF type and duration — paroxysmal AF responds best to ablation; the longer AF has been persistent, the more complex the procedure
• Left atrial size — a significantly enlarged left atrium is associated with lower ablation success rates
• Modifiable risk factors — uncontrolled hypertension, obesity, sleep apnoea and high alcohol intake all reduce ablation success rates, and addressing these before ablation is a priority
• Patient preference — this is genuine and important; some patients want the most definitive treatment available, others are cautious about procedures, and both positions are valid

What I always emphasise is that doing nothing is itself a choice — and the evidence increasingly suggests that early rhythm control leads to better long-term outcomes than waiting to see how symptoms evolve.

The Role of Lifestyle in All of This

Before recommending ablation, I invest significant time helping patients optimise their lifestyle. This is not a delaying tactic — it is sound medicine. Weight reduction, alcohol cessation or significant reduction, treatment of obstructive sleep apnoea, and optimal blood pressure control all improve ablation outcomes measurably. The LEGACY trial showed that weight loss of 10% or more reduced AF burden by over 50% in obese patients — comparable in some respects to the effect of ablation itself. For a substantial group of patients, lifestyle changes alone can dramatically reduce symptoms, though the evidence still supports ablation as the most effective long-term strategy for maintaining normal rhythm.

To discuss the right treatment strategy for your AF, book a consultation at OneWelbeck Heart Health — drboonlim.co.uk or call 0208 187 9888